[Ability of midregional proadrenomedullin (MR-proADM) to predict poor clinical outcome and stratify prognosis in adult patients seen for suspected infection in the Emergency Department]

What Was Tested

Researchers studied Adrenomedullin in this observational study publication.

To analyze and compare the accuracy of midregional proadrenomedullin (MR-proADM) to predict poor clinical outcome (understood as progression to septic shock or admission to the Critical Care Unit -CCU-) and 30-day mortality in adult patients seen for suspected infection in the Emergency Department (ED).

The researchers also compared their performance with other biomarkers (C-reactive protein -CRP-, procalcitonin -PCT-, lactate and leukocyte count) and clinical scales widely used in routine practice (qSOFA, SRIS, NEWS-2).

Who Took Part

PubMed indexes the participants as adults, middle-aged adults, older adults and people over 80, both men and women.

A prospective, observational and analytical study was carried out on adult patients who were treated in an ED with the clinical diagnosis of an infectious process.

How the Study Was Run

The main outcome was a composite measure that included progression to septic shock or admission to the CCU and 30-day mortality.

The predictive ability was analyzed with the area under the curve (AUC) of the receiver operating characteristic (ROC) and the values of sensitivity (Se), specificity (Sp), positive predictive value (PPV) and negative predictive value (NPV) of MR-proADM, PCR, PCT, lactate, leukocyte count and the clinical scales.

What Was Measured

The subject headings attached to it are Adrenomedullin, Protein Precursors, Emergency Service, Hospital, Prognosis, Biomarkers, Procalcitonin and Shock, Septic.

Author keywords: Emergency department, Infection, Mortality and Sepsis.

What This Means in Plain Language

This is an observational study of Adrenomedullin.

Results are reported in around 8 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2025 (Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia), a journal based in Spain.

More context: the Adrenomedullin compound page, all human trials.